Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract GvHD Through Enhanced Accumulation of Myeloid Derived Suppressor Cells by Bruce, Danny W et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract GvHD
Through Enhanced Accumulation of Myeloid Derived Suppressor
Cells
Citation for published version:
Bruce, DW, Stefanski, HE, Vincent, BG, Dant, TA, Reisdorf, S, Bommiasamy, H, Serody, DA, Wilson, JE,
McKinnon, KP, Shlomchik, WD, Blazar, BR, Zaiss, D, McKenzie, ANJ, Coghill, JM & Serody, JS 2017, 'Type
2 Innate Lymphoid Cells Treat and Prevent GI Tract GvHD Through Enhanced Accumulation of Myeloid
Derived Suppressor Cells' Journal of Clinical Investigation. DOI: 10.1172/JCI91816
Digital Object Identifier (DOI):
10.1172/JCI91816
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Clinical Investigation
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
 1 
Title:  Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract GvHD Through 
Enhanced Accumulation of Myeloid Derived Suppressor Cells 
 
Authors: Danny W. Bruce1, Heather E. Stefanski7, Benjamin G. Vincent1,3,4, Trisha A. Dant5, Shannon 
Reisdorf1, Hemamalini Bommiasamy1, David A. Serody1, Justin E. Wilson4, Karen P. McKinnon1,5, Warren D. 
Shlomchik8, Paul M. Armistead1,2, Jenny YP Ting1,4, John T Woosley6, Bruce R. Blazar7, Dietmar M. W. Zaiss, 
9Andrew N. J. McKenzie10, James M. Coghill1,3, and Jonathan S. Serody1,3,5 * 
 
Affiliations:  
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, 
USA. 
2Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. 
3Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. 
4Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. 
5Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, 
USA. 
6Department of Laboratory Medicine and Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC 
27599, USA. 
7Department of Pediatrics and University of Minnesota Cancer Center, Minneapolis, MN 55455, USA.  
8Department of Medicine and Cancer Center of the University of Pittsburgh, Pittsburgh, PA 15213, USA. 
9Centre for Immunity, Infection and Evolution, and the Institute for Immunology and Infection Research, School 
of Biological Sciences, University of Edinburgh, Edinburgh EH9 3FL, UK. 
10The MRC Laboratory of Molecular Biology, Cambridge CB2 OQH, UK. 
*
Corresponding Author: JSS, Room 5012, Marsico Hall, University of North Carolina School of Medicine, 
Chapel Hill, North Carolina 7599-7295, E-mail: Jonathan_Serody@med.unc.edu 
 
Conflict of interest: The authors have declared that no conflict of interest exists.   
 
One Sentence Summary:  Adoptive transfer of donor ILC2 cells effectively prevents and treats acute GvHD of 
the lower GI tract by increasing the number of GI tract myeloid-derived suppressor cells.    
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Abstract:  
Acute graft-versus-host disease (aGvHD) is the most common complication for patients undergoing allogeneic 
stem cell transplantation.  Despite extremely aggressive therapy targeting donor T cells, patients with grade III 
or greater aGvHD of the lower GI tract, who do not respond to therapy with corticosteroids, have a dismal 
prognosis.  This has increased interest in the function of local immune and non-immune cells in regulating the 
inflammatory process in the GI tract during aGvHD.  Here, we demonstrate using murine models of allogeneic 
bone marrow transplantation, that type 2 innate lymphoid cells (ILC2s) in the lower GI tract are sensitive to 
conditioning therapy and show very limited ability to repopulate from donor bone marrow.  Infusion of donor 
ILC2s was effective in reducing the lethality of aGvHD and in treating lower GI tract disease.  This was associated 
with reduced donor pro-inflammatory Th1 and Th17 cells, accumulation of donor myeloid derived suppressor 
cells (MDSCs) mediated by ILC2 production of IL-13, improved GI tract barrier function and a preserved graft-
versus-leukemia (GvL) response.  Infusion of donor ILC2s to restore gastrointestinal tract homeostasis may be 
critical for optimal treatment of severe lower GI tract aGvHD.   
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Introduction 
Allogeneic stem cell transplant (allo-SCT) has the potential to provide curative therapy for patients with 
high risk acute leukemia, lymphoid malignancies, and other malignant diseases (1-3).  Despite improvements in 
HLA-typing and stem cell donor selection, GvHD remains the major complication of allo-SCT with incidence of 
acute GvHD (aGvHD) ranging from 30-80% and accounting for 15-30% of mortality of transplant recipients (4, 
5).  Grade III-IV aGvHD involving the lower gastrointestinal tract is the most common cause of morbidity and 
mortality from aGvHD.  The administration of corticosteroids is the standard approach for the treatment of 
patients with grade II-IV aGvHD with approximately 70% of patients treated responding (6).  However, the long-
term survival of patients with corticosteroid non-responsive aGvHD involving the lower GI tract is dismal with 
less than 20% of those patients alive one year after diagnosis (7).  Clearly, new forms of therapy are needed for 
the treatment of patients with corticosteroid non-responsive aGvHD of the lower GI tract.   
Research over the past forty years has primarily focused on the role of donor derived T cells in the 
pathogenesis of aGvHD (8).  Work from both pre-clinical transplant models and from clinical transplant studies 
has indicated a critical role for T cells, specifically Th1/Tc1 T cells, in the pathophysiology of aGvHD.  Thus, the 
treatment of aGvHD has almost entirely focused on targeting donor T cells.  However, despite highly potent 
therapy targeting T cells such as alemtuzumab, outcome for patients with corticosteroid non-responsive aGvHD 
has not improved (7).  This has led to increasing interest in the role of other pro-inflammatory immune cells, such 
as macrophages, neutrophils and B lymphocytes in the pathophysiology of aGvHD, and the local function of anti-
inflammatory immune and non-immune cells (9, 10).   
A second group of immune cells that diminish the effector function of pro-inflammatory immune cells may 
be critical to the immune response during aGvHD.  FoxP3-expressing regulatory T cells (Tregs) limit the expansion 
and effector function of donor T cells.  Infusion of donor Tregs has been shown to be an effective prophylactic 
approach for the prevention of aGvHD (11). At this time, it is not clear if the infusion of Tregs can effectively treat 
on-going aGvHD.  Our group has shown that IL-13 activated bone marrow myeloid-derived suppressor cells 
(MDSC) used at the time of bone marrow transplant in pre-clinical models inhibited GvHD lethality (12).  
However, their ability to treat active aGvHD is quite modest.  Thus, despite intense research evaluating the 
function of immune cells that diminish effector T cell function, there is not a currently identified population of cells 
that has significant activity treating active aGvHD.   
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Over the past decade, a number of researchers have identified populations of innate immune cells (ILC) 
critical for rapid mucosal immune responses (13, 14).  The initial ILC described four decades ago was the NK 
cell.  Recently, multiple populations of ILCs that generate IFN-γ (ILC1), IL-5 and IL-13 (ILC2) and IL-17 and/or 
IL-22 (different subpopulations of ILC3 cells) have been described (15).  ILC2s, previously termed nuocytes or 
innate helper type 2 cells, express GATA-3 and ID-2 similar to Th2 cells.  They generate substantial type-2 
cytokines.  ILC2s, which respond to IL-25, are critical to the anti-helminth immune response and play an 
important role in allergen-induced inflammation (16-20).  The role of innate cells in the biology of aGvHD has 
been evaluated recently.  Hanash et al demonstrated that ILC3 cells in the GI tract were not sensitive to 
conditioning therapy but were decreased in mice with acute GvHD.  The loss of ILC3 cells was associated with 
decreased generation of IL-22, impaired epithelial barrier function, and diminished numbers of intestinal stem 
cells (21).  In humans, patients with decreased numbers of circulating CD69+ ILC2 and ILC3 cells had an 
increased risk of aGvHD (22).   
We hypothesized that unlike ILC3 cells, there was a population of innate lymphoid cells that was sensitive 
to conditioning therapy.  Here, we demonstrate that ILC2s in the GI tract but not in the lung are highly sensitive 
to conditioning therapy prior to allo-SCT and, more importantly, that there is quite limited repopulation of ILC2 
cells in the GI tract from donor bone marrow.  Infusion of IL-33 activated donor ILC2 cells significantly reduced 
GI tract associated aGvHD mortality, improving GvHD scores and associated weight loss in two separate murine 
models.  Additionally, ILC2 treatment of recipients with established aGVHD significantly increased survival.  
Finally, we provide a novel mechanism by which ILC2s recruit donor myeloid-derived suppressor cells (MDSCs) 
to the lower GI tract to mitigate aGvHD.  These studies strongly suggest that expanded ILC2s may be a potent 
cellular therapy for the treatment of lower GI tract aGvHD. 
 
Results 
Type 2 innate lymphoid cells are radiation sensitive   
To evaluate the effect of conditioning therapy on ILCs, we irradiated B6D2 mice and quantitated GI tract 
ILCs.  ILC3s in the lamina propria (LP) of the colon but not the mesenteric lymph node (MLN), isolated 24 hours 
after lethal irradiation were relatively resistant to radiation (Figure 1, A and B) (13, 21, 23).  In contrast, CD4+ T 
cells in the LP and lung were radiation sensitive.  Unlike ILC3s, ILC2s from the LP of the colon were highly 
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sensitive to radiation (Figure 1B).  Similar to ILC3s, ILC2s in the MLN and spleen were exquisitely sensitive to 
radiation (Figure 1B, Supplemental Figure 1A).  Interestingly, lung ILC2s were relatively resistant to radiation 
therapy (Figure 1B).  We also examined the effects of chemotherapy on ILC2s and found that they are 
significantly reduced within 24 hours of cyclophosphamide treatment in the LP and MLN (Figure 1C).   
Next, we evaluated the reconstitution of murine donor and recipient ILC2s four weeks after allo-SCT.  
Over this time period, there were extremely limited numbers of donor and/or recipient ILC2s in the LP of recipient 
mice that received irradiation and bone marrow without donor T cells, with a decrease in ILC2s in the LP at day 
28 compared to day 1 (Figure 1D).  By comparison, there were approximately 20-fold greater numbers of donor 
and/or host ILC2s in the lung on day 28 post-transplantation (Figure 1D).  Thus, ILC2s in the GI tract, but not the 
lung, are sensitive to conditioning therapy and have extremely limited repopulation kinetics from donor bone 
marrow in the first 4 weeks post-transplant.   
 
Co-infusion of ILC2s reduces aGvHD and increases recipient survival 
To evaluate the function of ex vivo ILC2s in GvHD biology, murine ILC2s were expanded as previously 
described (24), and their phenotype verifed by flow cytometry (Supplemental Figure 2, A, B, and C) and 
transcriptome analysis (Supplemental Figure 3, A and B; Supplemental Table 1).  Next, we performed survival 
studies in a murine model of allo-SCT with co-infused ILC2s.  Splenic donor C57BL/6 (B6) T cells with a 1:1 ratio 
of ILC2 (BM, T cells + WT ILC2) or without ILC2s (BM + T cells) were infused into lethally irradiated haploidentical 
recipients on day 0.  Co-transplantation of a single dose of ILC2s significantly improved survival with 70% of 
recipients surviving 60 days post-transplant (Figure 2A).  There was a significant reduction in both the clinical 
score and weight loss in mice receiving ILC2s (Figure 2, B and C).  On day 20, there was a decrease in pathology 
score in the colon and spleen (Figure 2D), with a non-significant decrease in the ileum and no difference in the 
lung and liver (Supplemental Figure 4A).  Using a 2:1 ratio of ILC2s to T cells, we repeated the survival studies 
in a B6 into BALB/c transplant model.  There was a significant improvement in survival (Figure 2E) and clinical 
GvHD score (Supplemental Figure 4B).  
 
Treatment of aGVHD with ILC2s 
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While the use of ILC2s to prevent aGvHD would be beneficial, clinically it would be more impactful to use 
these cells to treat active aGVHD.  ILC2s were infused 7 days after transplant, a time when donor T cells have 
initiated inflammation in GvHD target organs.  Infusion of a single dose of ILC2s significantly improved survival 
over untreated B6D2 recipients (Figure 2F).  In addition, there was a significant reduction in clinical GvHD score 
in recipients of ILC2s on day 7 (Figure 2G).  We repeated our day 7 treatment experiments in the complete MHC 
mismatch model and found significantly improved survival with ILC2 infusion (Supplemental Figure 4C).  These 
findings indicate that a single infusion of ILC2s can significantly improve survival after the onset of GvHD. 
 
ILC2s migrate to the GI tract and produce Th2 inducing cytokines 
We were interested in determining if ILC2s migrated to GvHD target organs after allo-SCT.  For this, we 
infused B6-GFP+ ILC2s into lethally irradiated B6D2 mice.  While at day 12 post-BMT only limited GFP signal 
was found in the LP, we observed large clusters of GFP+ ILC2s in Peyer’s patches (PPs) of the colon and small 
bowel (Figure 3A).  Evaluation of GFP+ ILC2s by flow cytometry confirmed that IL-33 activated cells had a surface 
phenotype similar to ex vivo expanded ILC2s (Figure 3B).  Greater than 90% of donor GFP+ ILCs in the GI tract 
expressed IL-13 (Figure 3D), while IL-5 expression varied with more than 40% of ILC2s in the GI tract expressing 
IL-5 (Figure 3C).  These findings indicate that ILC2s migrate to the GI tract, maintain their phenotype, and 
produce ILC2 signature cytokines. 
 
Infused ILC2s reduce GI tract T cell burden and limit Th1 and Th17 induction 
We evaluated the effect of the infusion of ILC2s on the generation of pro-inflammatory donor T cells in 
GvHD target organs.  Co-infusion of ILC2s reduced the accumulation of donor T cells in PP, the colon and small 
bowel as determined by GFP intensity (Figure 4A).  In addition, there was significantly less GFP in tissue 
homogenates (Figure 4B).  To confirm these findings, we analyzed T cell infiltration into the lungs, liver, spleen, 
MLN and colonic LP by flow cytometry (Figure 4C).  Recipients of ILC2s had a reduction in donor lymphocytes 
in the LP of the colon (Figure 4D), with significant reduction in donor CD8+ T cells (Figure 4E).  There were 
significant reductions in the total number of LP CD4+ and CD8+ T cells that expressed IFN- and CD4+ T cells 
that generated IL-17A (Figure 4F).  Infusion of ILC2 cells did not lead to a significant difference in the quantity of 
IFN- producing donor CD4+ or CD8+ T cells in other GvHD target organs (Supplemental Figure 5, A and B).  
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The decrease in IFN- producing CD4+ and CD8+ T cells in the colon was not associated with an increase in T 
cells generating IL-10 or an increase in FoxP3 expressing regulatory T cells (Tregs) (Supplemental Figure 5, C 
and D).  These data indicate that co-infusion of ILC2s is associated with a reduction in the number of pro-
inflammatory donor T cells generating IFN-γ and/or IL-17A in the GI tract. 
 
ILC2 suppression of aGvHD is independent of increased Th2 differentiation 
Conceivably, ILC2s could induce donor Th2 polarization, which would mitigate aGvHD (25).  To assess 
for Th2 cells after ILC2 infusion, we analyzed IL-4 production by donor T cells (Supplemental Figure 5E).  We 
did not observe an increase in IL-4 producing donor T cells in recipients of ILC2s in the colon (Supplemental 
Figure 5F).  To verify that the mechanisms behind ILC2 suppression of aGvHD are independent of the generation 
of Th2 cells, we performed survival studies using T cells from STAT6-/- mice (26).  Recipients of STAT6-/- T cells 
alone developed aGvHD with all recipients dying before day 30; however, 80% of recipients given STAT6-/- T 
cells with ILC2 cells survived long term with significantly reduced clinical scores by day 20 post-BMT 
(Supplemental Figure 5, G and H).  The ability of ILC2 cells to suppress aGvHD does not require the generation 
of donor Th2 cells. 
 
ILC2 infusion enhances LP myeloid cells  
We observed an increase in donor myeloid cells in the lower GI tract in recipients of WT ILC2s 
(Supplemental Figure 6, A and B).  We analyzed donor myeloid cells for expression of CD45, CD11b, Gr-1, Ly-
6C and Ly-6G, a phenotype that is consistent with myeloid-derived suppressor cells (MDSC), which have been 
shown to suppress aGvHD (Figure 5A)(12, 27).  We found a significant increase in donor MDSCs in the LP of 
colon and small bowel in ILC2 treated recipient mice (Figure 5B).  However, MDSCs were not increased in the 
lung or liver of recipients of ILC2 cells (Supplemental Figure 6C).  To test whether the function of ILC2s was 
dependent on MDSCs, we depleted myeloid cells using an anti-Gr-1 mAb in transplanted mice receiving either 
BM and T cells with or without donor ILC2 cells.  Depletion of Gr-1+ cells reduced the median survival of control 
BM and T cell recipients from 25 to 20 days (Figure 2A compared to Figure 5C).  In contrast, depletion of Gr-1+ 
cells completely ablated the beneficial effect of ILC2s, with no difference being observed in survival between 
mice receiving donor T cells with anti-Gr-1 antibody, or donor ILC2s with T cells and anti Gr-1 antibody (Figure 
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5C).  The ability of anti-Gr-1 mAb to abrogate the beneficial effects of donor ILC2 cells was dependent on the 
ability of ILC2 cells to prevent aGvHD as infusion of anti-Gr-1 mAb had no impact on the outcome of recipient 
mice receiving only donor bone marrow cells (Fig 5c).  There was a similar loss of efficacy of ILC2 infusion after 
depletion of Ly-6C+ cells (Supplemental Figure 6D).  Thus, the ability of ILC2s to prevent aGVHD is dependent 
on the presence of Gr-1+ cells. 
 
IL-13 is required for ILC2 induced donor MDSC suppression of inflammatory T cells 
Next, we performed survival studies to test the ability of IL-13-/- ILC2s to suppress aGvHD(12).  Compared 
to the infusion of BM + T cells alone, there was no significant improvement in median survival for mice receiving 
BM, T cells and IL-13-/- ILC2s (Figure 6A).  When compared to mice that received WT ILC2 treatment, only 25% 
of IL-13-/- ILC2 recipients survived long term as compared to 75% survival when WT ILC2 are given (Figure 6A).  
To further investigate the role of ILC2 derived IL-13 suppression of aGvHD, we evaluated IFN- and IL-17A 
expression by donor CD4+ and CD8+ T cells in the colon.  The decrease in T cells generating IFN- and/or IL-
17A observed in mice receiving WT ILC2s was lost after the infusion of IL-13-/- ILC2s (Figure 6B compared to 
Figure 4F).  In addition, IL-13-/- ILC2s failed to enhance donor MDSCs in GvHD target organs (Figure 6C and 
Supplemental Figure 6E).  These data indicate a critical role for IL-13 production by ILC2 cells to suppress donor 
T cell production of the pro-inflammatory cytokines IFN-γ and IL-17A.   
 To evaluate how ILC2 cells impact the presence of MDSCs, we co-cultured expanded ILC2s with BM 
derived MDSCs (BM MDSC) and quantified MDSCs 72 hours later.  BM MDSCs cultured with congenic ILC2s 
showed significantly enhanced survival over MDSCs cultured alone, MDSCs cultured in the presence of IL-13, 
and those cultured with IL-7 and IL-33 (Figure 6D).  However, BM MDSCs co-cultured with WT ILC2s survived 
significantly better than those cultured with IL-13 deficient ILC2s.  To evaluate if ILC2s and MDSCs require cell-
to-cell contact, we cultured both populations in plates across a semi-permeable membrane.  Enhanced survival 
of MDSCs by ILC2s was abrogated in the absence of cell-to-cell contact (Figure 6D).   
 
ILC2 infusions affect lower GI tract permeability 
Previous investigators have demonstrated a critical role for ILC2s in the maintenance of epithelial 
integrity(13).  Six days after BMT, we found there was no difference in intestinal permeability when comparing 
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non-irradiated age matched mice to BMT recipients of BM only, BM and T cells or BM, + T cells + WT ILC2 
(Figure 7A).  On days 12 and 20 post-transplant, recipients of donor T cells had significantly enhanced epithelial 
permeability compared to healthy B6D2 mice as well as recipients of BM only (Figure 7, B and C).  ILC2 treated 
mice had significantly improved epithelial integrity compared to control mice and showed no statistical difference 
compared to untreated B6D2 or recipients of bone marrow alone (Figure 7, B and C).  ILC2 infusion is associated 
with improved intestinal barrier function in the setting of reduced lower GI tract aGvHD.   
Activated ILC2s produce amphiregulin in response to IL-33 (Supplemental Table 1), which promotes 
wound healing and epithelial barrier repair (15).  We evaluated the ability of amphiregulin deficient ILC2s (Areg-
/- ILC2) to protect against aGvHD mortality.  Infusion of Areg-/- ILC2 cells with donor T cells and BM led to 
diminished overall survival compared to recipients of WT ILC2 cells (Figure 7D and Figure 2A).  However, the 
kinetics of the response differed from that found using IL-13-/- ILC2 cells with mortality occurring later post-
transplant (Figure 7D and Figure 6A).  The infusion of Areg-/- ILC2s failed to increase epthelial barrier integrity 
(Figure 7E).  Thus, the generation of amphiregulin by ILC2 cells is critical to the maintenance of the epithelial 
barrier in the GI tract mediated in part by ILC2 cells.   
 
ILC2 cells do not inhibit the Graft-versus-Leukemia (GvL) response 
The anti-tumor response mounted by donor T cells is key to the clinical efficacy of allo-SCT.  We tested 
the GvL response by giving allogeneic bone marrow transplant recipients, GFP-expressing blast crisis chronic 
myelogenous leukemia (BC-CML) tumor cells (28).  Recipients of donor T cells had significantly fewer tumor 
cells in the spleen compared to mice receiving TCD bone marrow alone and this effect was independent of the 
infusion of donor ILC2 cells (Figure 8A).  
 
Comparison of ILC2 to other cell therapy treatments for GvHD 
Multiple cell populations have been generated in an attempt to mitigate the incidence and/or severity of 
aGvHD.  Two populations that have recently been evaluated by our group are natural Tregs and IL-13 MDSCs 
(12, 29).  To compare the function of ILC2 cells with these other immunosuppressive cell populations, we infused 
Tregs or ILC2 cells with donor T cells, TCD bone marrow and luciferase expressing P815 (luc-P815) tumor cells.  
Mice that received BM and luc-P815 without T cells showed extensive tumor growth in the spleen, MLN and 
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inguinal lymph nodes.  Mice that received T cells efficiently eliminated tumor cells when ILC2 cells were given 
(Figure 8A).  In agreement with a previous report (30), infusion of 1:1 ratio of Tregs to splenic T cells led to 
suppression of aGvHD but with the loss of the graft-versus-tumor effect critical for allo-SCT (Figure 8B).  When 
we evaluated a lower dose of Tregs, (1:4 ratio) we found that the GvL response was preserved but that the majority 
of mice succumbed to GvHD (Fig 8B).  These findings indicate that the survival of B6D2 recipient mice 
transplanted with B6 donor T cells and P815 tumor cells is significantly improved with co-administration of ILC2 
cells compared to a 1:1 or 1:4 ratio of Tcon:Treg cells (Figure 8C).   
When given as treatment, MDSCs fail to suppress aGvHD (27).  ILC2s and MDSCs were given on day 7 
following allo-SCT in mice that received BM and splenic T cells.  When used therapeutically, MDSCs did not 
improve survival or clinical score compared to mice receiving donor T cells alone (Figure 8, D and E).  However, 
there was a significant improvement in the survival of mice receiving donor ILC2 cells with a significant reduction 
in clinical score (Figure 8, D and E).  Thus, ILC2 cells in vivo do not inhibit the GvL response found after the 
infusion of Treg cells and have significantly improved function to treat aGvHD compared to MDSCs.   
 
Human ILC2 Cell expansion 
While these findings indicate a critical role for the administration of donor ILC2 cells to control lower GI 
tract GvHD, for clinical translation, we needed to expand human ILC2 (hILC2) cells ex vivo.  We isolated CD34+ 
cord blood cells and cultured these cells with IL-33 and IL-2 with/without IL-25.  Culture with IL-2/IL-33 alone led 
to 2.5-3 log expansion of CRTH2+, CD161+ lineage negative hILC2 cells that peaked on day 18 (Figure 8F, 
Supplemental Figure 6F).  The addition of IL-25 allowed for the persistent expansion of hILC2 cells through day 
21.  Thus, human ILC2 cells can be expanded ex vivo from CD34+ cord blood progenitors.   
 
Discussion 
Steroid refractory aGvHD of the lower GI tract is the most common cause of morbidity and mortality in 
patients that develop aGVHD after stem cell transplantation.  Here, we demonstrate that the administration of 
donor ILC2s at the time of allo-SCT and up to one week after transplant significantly improved survival and 
clinical GvHD scores.  ILC2s did not abrogate the anti-tumor GvL response, which may not be surprising given 
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their primary function in the lower GI tract, which is not the site of tumor growth in our models or for patients 
undergoing allo-SCT.  Thus, ILC2 infusions represent a novel approach to therapy for lower GI tract GvHD.  
One complication of allo-SCT is the incomplete reconstitution of immune cells from donor bone marrow.  
Some cell populations, such as B-1 lymphocytes, are generated preferentially from fetal liver and/or bone marrow 
and not adult bone marrow cells(31).  In contrast, ILC2s in the GI tract, which have been shown to derive from 
adult bone marrow precursors, have extremely slow reconstitution kinetics after bone marrow transplantation.  
We find significantly decreased numbers of both donor and host ILC2s with a greater decrease at day 28 
compared to day 1 after allo-SCT.  These findings support clinical data regarding the paucity of circulating ILC2s 
12 weeks after allogeneic stem cell transplantation (32) .  There are at least two potential hypotheses for the 
impaired recovery of ILC2 cells from donor bone marrow after allogeneic bone marrow transplantation.  First, 
despite their generation from bone marrow cells during development, ILC2 precursor cells may not be effectively 
generated from adult bone marrow precursor cells.  In support of this hypothesis, a recent publication 
demonstrated poor recovery in patients with the common γ-chain deficiency or JAK3 mutation of ILC cells, other 
than ILC1 cells, after stem cell transplantation.  Interestingly, the impaired recovery of ILCs after stem cell 
transplantation was much greater in patients receiving non-myeloablative conditioning therapy.  The impaired 
recovery of ILC cells after transplant was not associated with an increased risk of infectious diseases suggesting 
that ILC cells may not be critical in the presence of T and B cells for the control of infectious pathogens (33).  
Our findings suggest that ILC cells may only be critical in specific uncommon settings such as assisting in the 
control of the persistent inflammation in the GI tract during severe aGvHD.  Thus, a substantial number of patients 
after allogeneic SCT may function normally in the absence of a sufficient number of ILC2 cells.  A second 
hypothesis is that ILC2 precursor cells are present in the donor bone marrow population but that cellular plasticity 
and the significant pro-inflammatory environment after allogeneic bone marrow transplantation in the lower GI 
tract converts these ILC2 precursor cells to ILC1 and/or ILC3 cells (34-36).  Both of these mechanisms could 
contribute to the poor recovery of ILC2 cells in mice after allogeneic BMT.   
 ILC2s have been found to impact the presence of alternatively activated macrophages (37).  We are the 
first to demonstrate a role for ILC2s in the presence of MDSCs, which required ILC2 production of IL-13.  Previous 
studies have shown that IL-13 is capable of activating MDSCs through activation of STAT1 and STAT6, this 
leads to upregulation of arginase and INOS, which are critical to the immunosuppressive function of MDSCs (38, 
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39).  Stromal cell production of IL-13 has been demonstrated to be important in this process(40).  Here we 
demonstrate that ILC2s can maintain the viability of MDSCs in vitro.  This process requires IL-13 generated by 
ILC2s and cell-to-cell contact between MDSCs and ILC2s.  How this functions in vivo is a current focus.   
 IL-33, which is critical for the generation of ILC2 cells, is a ligand for the IL-33 receptor also termed ST2.  
Previous work evaluating biomarkers as predictors of outcome for patients undergoing allogeneic stem cell 
transplantation has found that elevation of ST2 was associated with a lack of therapeutic response for GVHD on 
day 28 post-transplant and increased mortality six months after transplantation (41).  In those evaluations, ST2 
levels were greater for patients undergoing myeloablative compared to reduced intensity conditioning regimens.  
These data were confirmed in a study of recipients of cord blood transplantation (42).  We have shown that 
increased generation of IL-33 post-transplantation is associated with increased severity of GvHD in murine 
models (43), and our group and another have found that blocking the interaction of IL-33 with the IL-33 receptor 
(ST2) diminished aGvHD (44).  We hypothesize that the increased levels of ST2 post-transplant are, in part, due 
to the loss of ILC2 cells in the GI tract that would respond to IL-33.  Persistent inflammation in the GI tract would 
lead to increased production of soluble ST2, which would be greater after myeloablative conditioning therapy 
due to the greater loss of ILC2 cells from the increased dose of chemotherapy or irradiation.  Our data would 
suggest that infusion of donor ILC2 cells, by markedly decreasing the accumulation of IFN-γ and IL-17 producing 
T cells in the GI tract, diminishes this pro-inflammatory environment.  We hypothesize that ST2 levels would 
significantly decrease after ILC2 infusion, which is currently being evaluated.   
 AREG is a member of the epithelial growth factor receptor family and plays a critical role in wound healing 
after injury(45).  Basophils, mast cells, CD4+ T cells, eosinophils, dendritic cells in addition to ILC2 cells can 
generate AREG.  In some specific instances, FoxP3+ Tregs that express the IL-33 receptor (ST2) can generate 
AREG.  Our data is consistent with a critical role for the production of AREG by ILC2 cells in their function to 
promote lower GI tract barrier function.  However, we did not determine the relative contribution of ILC2 cells to 
the generation of AREG in the lower GI tract post-transplant.  Future work is required to determine if AREG 
production by these other immune cells (and by non-immune cells) is critical to promoting GI tract epithelial 
integrity after the development of acute GvHD.   
There are several additional questions that remain to be addressed from our findings.  It is not clear the 
mechanism for the tissue-specific effects of conditioning therapy on ILC2 cells found in the lung compared to 
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those in the GI tract.  This could be related to differences in the microbiota at each site.  Alterations in the 
microbiome after conditioning therapy could activate ILC2 cells in the GI tract leading to enhanced depletion of 
cycling ILC2 cells after conditioning therapy.  Furthermore, there are clear differences in the supporting immune 
and non-immune cells at each site that also could play a role in the cell cycle status of ILC2 cells in the lung 
compared to the GI tract.  Finally, how ILC2 and ILC3 cells interact during aGvHD is not clear.  As our hypothesis 
focused on the effects of conditioning therapy on regulatory immune populations in the GI tract, and since ILC3 
cells in the GI tract are not depleted by conditioning therapy, we have not performed evaluations focusing on 
these cells.   
In conclusion, we demonstrate that restoration of ILC2s can treat GI tract aGvHD, is dependent on the 
generation of IL-13 and amphiregulin by the ILC2s, and unlike Tregs does not impact the GvL response.  These 
findings provide strong pre-clinical rationale for testing the infusion of ILC2 cells to treat patients with steroid non-
responsive lower GI tract GvHD.   
 
Materials and Methods 
Mice 
C57BL/6J (termed B6), BALB/cJ, B6.129S2 STAT6-/- (termed STAT6-/-) and C57BL/6J × DBA/2 F1 (termed 
B6D2) were purchased from The Jackson Laboratory.  The generation of enhanced GFP-expressing C57BL/6 
mice has been described previously (46).  C57BL/6 IL-13 eGFP and mice C57BL/6 Areg-/- mice have been 
described previously (24, 47).  Donor and recipient mice were age-matched males between 8 and 16 wk.  All 
experiments were performed in accordance with protocols approved by the University of North Carolina 
Institutional Animal Care and Use Committee. 
 
Isolation and expansion of murine ILC2s and MDSCs 
10 to 12 week old B6 mice were given 0.4 µg of recombinant mouse IL-17E/IL-25 (R&D Systems, Minneapolis, 
MN) by IP injection for 4 days.  On day 5, cells were isolated from the MLN and peritoneum by peritoneal lavage 
using RPMI with 10% fetal bovine serum (Complete media).  ILC2s were isolated by negative selection with a 
MACs column using biotinylated antibodies [(Anti-CD8α (53-6.7), anti-CD4 (RM 4.4), anti-CD3ε (145-2C11), anti-
γδTCR (UC7-13DS), anti-TER119 (TER-119), anti-B220 (RA3-6B2), anti-CD11b (M1/70), anti-NK1.1 (PK136) 
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(eBioscience, San Diego CA), anti-CD11c (N418), anti-CD19 (MB19-1), anti-Ly6G (1A8) and anti-CD49b (DX5) 
(BioLegend, San Diego CA] and Streptavidin Microbeads (Miltenyi 130-048-101).  Cells were cultured for six 
days in complete media with rIL-7 and rIL-33 (10ng/ml) (PeproTech, Rocky Hill, NJ) changing the media every 
2 days.  ILC2 activation was evaluated using flow cytometry on day 6 by IC staining of IL-5 and IL-13.  For BM-
MDSCs, freshly isolated CD90 depleted BM was plated at 3.0 x 105 cells/ml and incubated 4 days with 250U/ml 
recombinant GM-CSF (315-03) and 100ng/ml G-CSF (250-05) (PeproTech, Rocky Hill, NJ).  On day 4, 80ng/ml 
recombinant IL-13 (210-13) (PeproTech, Rocky Hill, NJ) was added to the cultures.  After 4 days, CD11b+ cells 
were isolated by magnetic bead separation using the Miltenyi CD11b+ selection kit (130-049-601) (Miltenyi 
Biotec, Bergisch Gladbach, Germany).  CD11b+ cells were analyzed for expression of GR-1; approximately 96% 
of the live cells were CD11b+/GR-1+.  For ILC2/MDSC co-culture experiments, ILC2s and MDSCs were plated 
at a 1:1 ratio at a density of 2.0 x 105 cells/ml, in conventional 24 well plates or in 5.0 µM filter transwell plates, 
with either 10ng/ml IL-7 and IL-33 or 80ng/ml IL-13 for 3 days before quantitation of live MDSCs by flow 
cytometry. 
 
RNA seq evaluations 
RNA was extracted from cultured ILC2s using the RNEasy mini kit (Qiagen) and mRNA sequencing libraries 
were prepared according to the TruSeq protocol (Illumina).  For mRNA-sequencing, samples were processed 
as previously described by The Cancer Genome Atlas(48).  Bases and QC assessment of sequencing were 
generated by CASAVA 1.8.  QC-passed reads were aligned to the murine reference genome using MapSplice 
(49).  Aligned reads were sorted and indexed using SAMtools, and then translated to transcriptome coordinates 
and filtered for large inserts and zero mapping quality using UBU v1.0 (https://github.com/mozack/ubu website).  
For the reference transcriptome, UCSC murine knownGenes (50) was used, with genes located on non-standard 
chromosomes removed.  The abundance of transcripts was then estimated using an Expectation-Maximization 
algorithm implemented in the software package RSEM (51) v1.1.13.  Estimated counts were normalized to the 
upper quartile(52) prior to comparison of expression across protocols.  Normalized counts were converted to 
expression rank values for comparison with microarray data.  RNA-Seq raw data files will be submitted to the 
NCBI GEO archive. 
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Comparison of ILC2 mRNA-seq with published microarray data 
Murine ILC gene signatures and raw microarray data were extracted from Robinette et. al. and relevant NCBI 
GEO datasets(53).  Microarray data were processed in R (http://www.R-project.org, R Development Core Team, 
Vienna, Austria) to determine transcript relative expression values using the Robust Multichip Average algorithm 
implemented in the oligo package(54).  Transcript-level inference of relative expression was done by cross-
referencing normalized probe signal values with the ‘mogene10sttranscriptcluster’ database (Affymetrix).  
Normalized signal values were converted to expression rank values for comparison with mRNA-seq data.  
Spearman rank correlations between gene expression values of ILC-associated genes for measured ILC2 (n = 
6) and published ILC1 (n = 2, 12 comparisons), ILC2 (n = 2, 12 comparisons), and ILC3 (n = 8, 48 comparisons) 
were calculated and used as a statistic.  Significance between sample groups was evaluated using the Kruskal-
Wallis test.  Mean rank expression values for each gene from each published group were plotted against mean 
rank expression values in the cultured ILC2s.  Significance was tested using the ‘cor.test’ module in R (method 
= ‘spearman’).  
 
Transplantation models 
Total T cells were isolated using a Cedarlane T cell recovery column kit (Cedarlane Laboratories, Burlington, 
NC), followed by antibody depletion using PE-conjugated anti-mouse B220 (RA3-B62) and anti-mouse CD25 
(3C7) Abs (eBioscience, San Diego, CA) and magnetic bead selection using anti-PE beads (130-0480801) 
Miltenyi Biotec, Cambridge, MA).  T cell depleted (TCD) bone marrow was prepared as described previously 
(55).  The day prior to transplantation, recipient mice received either 950 cGy (B6D2) or 800cGy (BALB/c) of 
total body irradiation.  For the B6, IL-13-/-, Areg-/- and STAT6-/- into B6D2 or B6 into BALB/c transplants, recipients 
were intravenously injected with either 4 × 106 T cells and 3 × 106 TCD BM cells, or 5 × 105 total T cells and 5 × 
106 TCD BM cells, respectively.  For ILC2 treatment groups, B6D2 or BALB/c recipients also received 4 x 106 or 
1 x 106 CD90+ ILC2s respectively.  Recipients were monitored twice a week and scored for clinical GvHD 
symptoms (designated as “Clinical Score”) using a semi-quantitative scoring system as previously described (56, 
57); animals were coded for these evaluations.  The sample size was chosen for the effect size needed based 
on our previous experience with sample sizes needed to demonstrate a significant difference in GvHD scoring 
between control and treated groups. Investigators were blinded to the clinical score and the pathological 
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evaluations.  For the scoring evaluation experiments, the inclusion of 9-12 recipients provided a power of 90% 
to detect a difference of 14 days in the median GvHD score of > 5 with an alpha error of < 0.05 between control 
and treated groups.  For all experiments, a control group received TCD bone marrow alone without additional T 
cells, which controlled for the presence of T cells in the marrow inoculum and potential infectious complications 
during aplasia.  MDSC depletion was performed by IP injecting recipients twice weekly starting on day 7 with 
200µg anti-GR-1 antibody (RB6-8C5) or anti-Ly-6G antibody (Monts-1;BioXCell, West Lebanon, NJ) until the 
termination of the experiment. 
Evaluation of radiation and chemotherapy sensitivity 
B6D2 mice received 950 cGy of total body irradiation or cyclophosphamide (200mg/kg) (Santa Cruz, sc-219703, 
Dallas TX.) by intraperitoneal injection.  24 hours or 28 days later cells were isolated from the LP, MLN and 
spleen for evaluation by flow cytometry.  Quantitation of ILCs was performed using the absolute event count of 
live cells gated as lineage negative and CD90+.  Expression of ICOS+ or RORγt+ were used to enumerate ILC2 
or ILC3 cells, respectively.  
 
Fluorescence stereo-microscopy and GFP quantification 
Organs from anesthetized animals were imaged with a Zeiss SteReo Lumar V12 microscope with GFP bandpass 
filter (Carl Zeiss MicroImaging, Inc.) at room temperature.  AxioVision (Carl Zeiss) software was used to 
determine GFP intensities.  Control and treatment recipient organs were imaged using the identical magnification 
(mag) and exposure (exp) times on day +12: PP-exp 200 ms, mag 40x.  Organs from recipient animals were 
homogenized and absolute GFP levels were determined by ELISA (Cell Biolabs, AKR-121).  No GFP is found 
in mice receiving sham treatment.  Detailed experimental procedures were conducted as described previously 
(55). 
 
Cell isolation from GvHD target organs 
Spleen, liver, lung, MLN and colon were excised and weighed.  LP lymphocytes were isolated using the Miltenyi 
LP dissociation kit (130-097-410) as per the manufacturer’s instructions.  Livers and lungs were digested in a 
solution of 1 mg/ml collagenase A (Roche) and 75 U of DNase I (Sigma-Aldrich, St. Louis, MO) in RPMI 1640/5% 
newborn calf serum.  Digested tissues were treated with ACK lysis buffer to remove RBCs and were passed 
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through 100-µm pore size cell strainers.  Leukocytes were collected at the interface of a 40%/80% Percoll 
(Sigma-Aldrich) gradient in RPMI 1640/5% newborn calf serum.  The pelleted cells were washed in PBS/2% 
FBS.  Spleens and MLN were teased apart, treated with ACK lysis buffer, and washed in PBS/2% FBS. 
 
Graft-versus-leukemia analysis 
BMT were performed as described and at the time of transplant B6D2 recipients were given 2.5 x 104 GFP+BC-
CML or luciferase-expressing P815 (Luc-P815 tumor cells (ATCC TIB-64) (Lentivirus BLIV101PA-1, System 
Biosciences, Mountain View CA).  Recipients of BC-CML tumor were euthanized 21 days post-BMT and 
splenocytes were evaluated for GFP expression by flow cytometry.  Regulatory T cells were isolated from B6 
splenocytes using the CD4+CD25+ Regulatory T Cell Isolation Kit (130-091-041) (Miltenyi Biotec, Bergisch 
Gladbach, Germany).  Recipients of Luc-P815 were monitored for survival and tumor infiltration via luciferase 
imaging on the IVIS Kinetic Optical System.  Mice received 3 mg D-luciferin (PerkinElmer) 10 minutes prior to 
imaging.  These cell lines were validated by MHC typing, GFP or luciferase expression and growth parameters. 
 
Flow cytometry analysis 
ILC2s were evaluated by flow cytometry for linage markers (88-7772), and CD90 (HLS51), ICOS (7E.17G9), 
CD127 (A7R34), T1/ST2 (RMST2-2), Sca-1 (D7), CD44 (IM7), CD25 (PC61.5), GITR (DTA-1) and intracellular 
staining for IL-4 (11B11), IL-13 (eBio13A), IL-5 (TRFK5), IFN- (XMG1.2), and IL-22 (1H8PWSR).  T cells were 
evaluated by surface staining of H2Kd (34-1-2S), CD4 (GK1.5), CD8 (53-6.7) and intracellular staining for IFN- 
(XMG1.2), IL-17 (ebio17B7), IL-4 (11B11), IL-10 (JESS-16E3) and FoxP3 (FJK-16s).  For analysis of MDSCs, 
donor cells were stained for the surface markers: CD45 (30-F11), CD11b (M1/70), CD11c (N418), GR-1 (RB6-
8C5), Ly-6C (HK1.4) and Ly-6G (1A8) (eBiosience, San Diego CA). Sample acquisition was performed using a 
BD FACs CANTO or BD LSR Fortessa (BD Bioscience, East Rutherford NJ.).    
 
FITC-Dextran permeability assay 
Intestinal permeability was assessed by luminal enteral administration of FITC-dextran 4000 (Sigma), a non-
metabolizable macromolecule that is used as a permeability probe.  Mice were fasted for 4 hours prior to gavage 
with FITC-dextran (40mg/100g of body weight).  After 4 hours, whole blood was collected by cardiac puncture 
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and FITC-dextran measurements were performed in triplicate by fluorimeter using a PerkinElmer “EnSpire” 
multimode reader.  Dilutions of FITC-dextran in PBS were used as a standard curve and absorption of 50 µl of 
serum or standard was measured at 488nm. 
Expansion of human ILC2s 
Isolated CD34+ cells from frozen umbilical cord blood cells (UCB) (NHLBI Umbilical Cord Blood Unit) were 
expanded with (50 ng/ml) IL-6, Flt3L, SCF, TPO  (PeproTech, Rocky Hill, NJ) and 750 nM SR1 (Sigma-Aldrich, 
St. Louis, MO) for 15 days.  Cells were then cultured in 24 well plates with 0.5 x 106/ml with 100U/ml of IL-2, 
50ng/ml of IL-25 and 50ng/ml of IL-33 (PeproTech, Rocky Hill, NJ), with RPMI containing 10% human Ab serum 
(Valley Biomedical, Winchester, VA) and 1% penicillin and streptomycin (Thermo Fisher Scientific, Waltham, 
MA).  Cytokines were replenished every three days.  On days 5, 10, 15, 20, and 25, cells were harvested and 
flow cytometry was performed.  Human ILC2s were characterized as CRTH2+ (BM16) CD161+ (HP-3G10) and 
T cell (OKT3), B cell (HIB19), monocyte (P67.6) lineage-negative cells.    All antibodies were purchased from 
eBiosicence, San Diego, CA.   
  
Statistical Evaluations 
Survival differences were evaluated using a Mantel–Cox log-rank test.  Survival curves were generated using 
the Kaplan–Meier method.  Differences in GvHD clinical and pathology scores were determined using a two way 
ANOVA, with Bonferroni correction for repeated measures of multiple comparisons.  Statistical analysis of RNA-
seq data described above. Unless otherwise noted in the figure legends, all other continuous variables were 
compared using the two tailed Student’s t test with Welch’s correction.  A p value of <0.05 was considered 
statistically significant. 
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Figure 1. ILC2s are sensitive to radiation and chemotherapy conditioning.  (A) Flow cytometry gating 
scheme used to define ILC2 and ILC3 cell subsets in mesenteric lymph node (MLN).  (B) Quantitation by flow 
cytometry of innate lymphoid and CD4+ T cells in the lamina propria (LP), MLN, or lung in mice without irradiation 
(white bars) or 24 hours after receiving radiation (950cGy) (grey bars).  These represent 3 independent 
experiments, n=5 for each group.  (C) Quantitation of ILC2s in the LP and MLN in mice receiving no therapy 
(white bars) or 24 hours after receiving 200 mg/kg of cyclophosphamide (grey bars).  These represent two 
independent experiments, n=4 for each. (D) Quantitation of host and donor derived ILC2s in the LP and lung 28 
days post- BMT, mean ± SEM.  These represent two independent experiments, n=5 Statistical analysis by 
student’s t-test with Welch’s correction, ** p<0.01, * p<0.05.   
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Figure 2. Co-transplantation of donor ILC2s reduces aGvHD incidence.  Lethally irradiated B6D2 mice 
received TCD BM (BM only), BM plus total splenic T cells (BM + T cells) or BM plus T cells with activated ILC2s 
(BM, T cells + WT ILC2). (A) Kaplan-Meier plot of survival following allo-SCT, one representative of 3 
experiments shown (n=8 each experiment), Log-rank (Mantel-cox) test, *** p<0.001.  (B) Clinical score and (C) 
percentage of body weight change post-transplantation, analyzed by 2 way ANOVA, with Bonferroni correction 
for repeated measures of multiple comparisons, *** p<0.001.  (D) Pathology scores of histological evaluations of 
GvHD target organs, 20 days post BMT (n=4 mice per group), student’s t-test with Welch’s correction, * p<0.05.  
(E) Kaplan-Meier plot for irradiated BALB/c mice that received TCD BM (BM only), BM plus splenic T cells (BM 
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+ T cells) or BM plus T cells with ILC2s (BM, T cells + WT ILC2).  This represents 2 independent experiments, 
n=14. Log-rank (Mantel-cox) test, *** p<0.001.  (F) Kaplan-Meier plot for B6D2 recipients that received BM alone 
(BM only), BM and splenic T cells (BM + T cells) and WT ILC2s either at the time of transplant [BM, T cells + WT 
ILC2 (Day 0)] or 7 days after transplant [BM, T cells + WT ILC2 (Day 7)], represents two experiments, n = 12 
total in each group, Log-rank (Mantel-cox) test, *** p<0.001.  (G) Clinical score of recipients from (Figure 2F), 
analyzed by 2-way ANOVA, with Bonferroni correction for repeated measures of multiple comparisons, ** p<0.01. 
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Figure 3. ILC2 evaluation in tissues post-transplant. (A) Fluorescence microscopy of B6-GFP ILC2s in 
Peyer’s patches 12 days after BMT, GFP imaging (left) and signal intensity (right), 40x magnification, exposure 
200 msec.  These data represent 3 experiments, n=6 each.  (B) Flow cytometry plots of B6-GFP ILC2 phenotype 
in the LP of BMT recipients 12 days after transplant, gated first as GFP+.  (C) Percentage of B6-GFP ILC2s 
expressing IL-13 and IL-5, average ± SEM.  These represent 3 independent experiments, n=5 each.   
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Figure 4. Co-transplantation of WT ILC2s reduces pro-inflammatory donor T cells numbers in the GI tract.  
Donor T cells were evaluated in the GI tract 12 days post-transplant using GFP+ splenic T cells alone (BM + T 
cells) or GFP+ T cells and WT ILC2s (BM, T cells + WT ILC2).  (A) Fluorescence microscopy of B6-GFP donor 
T cells in Peyer’s patches, GFP imaging (top row) and signal intensity (bottom row), 40x magnification, exposure 
200 msec.  (B) ELISA quantification of GFP in tissue homogenates from BM + GFP+ T cells (black dot) and BM, 
GFP+ T cells + WT ILC2 (open circle) normalized to grams of tissue.  Represents three experiments (n=5 each), 
student’s t-test with Welch’s correction, * p<0.05, **p<0.01.  Donor T cells from BMT were evaluated by flow 
cytometry 12 days after BMT.  (C) Density plots and gating scheme for the evaluation of donor T cells and 
intracellular cytokine expression from colon.  (D) Percentage of donor T cells in the LP BM + T cells (black dots) 
and BM, T cells + WT ILC2 (open cirlces).  (E) The total number of CD4+ and CD8+ donor T cells in the LP.  (F) 
Total number of IFN- producing donor CD4+ and CD8+ T cells and the number of donor CD4+ T cells producing 
IL-17A in the LP.  These data represent two independent experiments (n=5), student’s t-test with Welch’s 
correction, * p<0.05, **p<0.01.   
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Figure 5. Co-transplantation of WT ILC2s increases MDSC numbers in the GI tract.  (A) Representative 
density plots of CD11b+/GR-1+/Ly-6C+/Ly-6G+ MDSCs (gated on donor CD45+cells) 12 days after BMT.  (B) 
Frequencies of MDSCs as a percentage of CD45+ granulocytes in the colon and small bowel of BMT recipients 
12 days post-transplant. These represent 2 independent experiments, bar graphs are average ± SEM, student’s 
t-test with Welch’s correction, * p<0.05, ** p<0.01. (C) Kaplan-Meier plot showing results of Gr-1 depletion.  
Lethally irradiated B6D2 mice (950cGy) received 3.0 x 106 TCD BM (BM only), BM plus 4.0 x 106 total splenic T 
cells (BM + T cells) or BM plus T cells with 4.0 x 106 IL-33 activated ILC2s (BM, T cells + WT ILC2).  One group 
additionally received 200µg anti-GR-1 (α-GR-1) with another group receiving isotype control antibody twice 
weekly beginning 7 days post-transplant.  One representative of 2 independent experiments shown, n=6 per 
group.   
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Figure 6. Reduced efficacy of ILC2s in the absence of IL-13.  B6D2 recipients of B6 TCD BM (BM only), BM 
plus splenic T cells (BM + T cells) or BM plus T cells with cultured IL-13-/- ILC2 (BM, T cell + IL-13-/- ILC2) were 
evaluated for (A) Kaplan-Meier plot of survival following allo-SCT, one representative of 2 combined experiments 
shown (n=8 per group in each experiment).  WT ILC2 group shown represents one experiments from figure 2A.  
Immune infiltrates were evaluated in GvHD target organs by flow cytometry 12 days after allo-SCT with or without 
IL-13-/- ILC2.  (B) Total number of IFN- producing donor CD4+ and CD8+ T cells and the number of donor CD4+ 
T cells producing IL-17A in the colon LP.  These data represent two independent experiments, mean ± SEM 
(n=5 each).  (C) Frequencies of CD11b+/GR-1+/Ly-6C+/Ly-6G+ MDSCs (gated on donor CD45+cells) MDSCs in 
the colon and small bowel of BMT recipients of IL-13-/- ILC2s 12 days post-transplant.  These represent 2 
independent experiments, mean ± SEM.   (D) BM MDSC were co-cultured for 72 hours with WT or IL-13-/- ILC2 
(1:1), MDSC alone or with either IL-13 (80 ng/ml) or IL-7 & IL-33 (10 ng/ml each).  BM MDSC were co-cultured 
WT or IL-13-/- ILC2 (1:1) in transwell assays, alone, or in the presence of IL-13 only.  These represent 2 
independent experiments, mean ± SEM, 1-way ANOVA with Bonferroni’s correction for multiple comparisons, * 
p<0.05, ** p<0.01,  *** p<0.001. 
B
C
A
D
Figure 6
Days post-BMT
P
e
rc
e
n
t 
s
u
rv
iv
a
l
0 20 40 60
0
50
100
BM + T cells BM, T + IL-13-/-ILC2
BM only BM, T + WT ILC2
*
IFN-
C
D
4
+
C
e
lls
 (
1
0
3
)
B
M
 +
 T
 c
el
ls
 
B
M
, T
 c
el
ls
 +
 IL
-1
3
-/-  I
LC
2
0
5
10
IL-17A
C
D
4
+
 C
e
lls
 (
1
0
3
)
B
M
 +
 T
 c
el
ls
 
B
M
, T
 c
el
ls
 +
 IL
-1
3
-/-  I
LC
2
0
1
2
3
4
IFN-
C
D
8
+
 C
e
lls
 (
1
0
4
)
B
M
 +
 T
 c
el
ls
 
B
M
, T
 c
el
ls
 +
 IL
-1
3
-/-  I
LC
2
0.0
0.5
1.0
1.5
2.0
Colon LPL
%
o
f 
D
o
n
o
r 
C
D
4
5
+
B
M
 +
 T
 c
el
ls
B
M
, T
 c
el
ls
 +
 IL
-1
3
-/-  I
LC
2
0.0
0.5
1.0
1.5
2.0
Sm Bowel
%
o
f 
D
o
n
o
r 
C
D
4
5
+
B
M
 +
 T
 c
el
ls
B
M
, T
 c
el
ls
 +
 IL
-1
3
-/-  I
LC
2
0.0
0.2
0.4
0.6
0.8
M
D
S
C
 (
1
0
3
)
M
D
SC
 +
 W
T 
IL
C
2
M
D
SC
 +
 IL
-1
3
-/-  I
LC
2
M
D
SC
 o
nl
y
M
D
SC
 +
 IL
-1
3
M
D
SC
 +
 IL
-7
 &
 IL
-3
3
M
D
SC
 +
 W
T 
IL
C
2 
(tr
an
sw
el
l)
M
D
SC
 +
 IL
-1
3
-/- IL
C
2 
(tr
an
sw
el
l)
0.0
0.5
1.0
1.5
2.0
2.5 *
*
***
***
 30 
 
Figure 7. ILC2 treatment improves intestinal barrier function and does not abrogate the GvL response.  
Quantification of FITC-dextran in the serum of BMT recipients (A) 6 days, (B) 12 days, and (C) 20 days after 
transplant.  One representative of 2 independent experiments shown, mean ± SEM (n=5 per group).  Statistical 
analysis by 1-way ANOVA with Bonferroni’s correction for multiple comparisons; * p<0.05, ** p<0.01, *** p<0.001.  
(D) Kaplan-Meier plot of B6D2 recipients of B6 TCD BM (BM only), BM plus splenic T cells (BM + T cells) or BM 
plus T cells with cultured Areg-/- ILC2 (BM, T cell + Areg-/-ILC2) were evaluated for survival following allo-SCT, 
one representative of 2 experiments shown (n=5 per group in each experiment). WT ILC2 group shown 
represents one experiments from figure 2A.  (E) Quantification of FITC-dextran in the serum of BMT recipients 
20 days after transplant.  One combined representative of 2 independent experiments shown, mean ± SEM (n=5 
per group).  
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Figure 8.  Comparison of ILC2s and other cellular therapies for GvHD.  (A) Percentage of GFP+ BC-CML 
tumor in host spleen 21 days after BMT in the B6 into B6D2 model.  Represents two independent experiments 
(n=8 each). Analysis by student’s t-test with Welch’s correction, *** p<0.001.  (B) IVIS imaging of Luc-P815 tumor 
in B6D2 BMT recipients 15 days after transplant comparing recipients of BM and Luc-P815 cells (BM only), BM 
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with splenic T cells and Luc-P815 cells (BM + T cells),  BM, splenic T cells, Tregs and Luc-P815 cells (BM, T cells 
+ Treg) and BM, splenic T cells, WT ILC2 and Luc-P815 cells (BM, T cells + WT ILC2); represents two independent 
experiments n = 5 in each group.  (B) Kaplan-Meier plot comparing the survival of the allo-SCT recipient’s 
described in (A). Log-rank (Mantel-cox) test, ** p<0.01.  (D) Kaplan-Meier plot comparing the survival of 
recipients of allo-SCT (B6 into B6D2 model) that received BM alone (BM only), BM and splenic T cells (BM + T 
cells), and those that received BM and splenic T cells at the time of transplant with either WT ILC2 (BM, T cells 
+ WT ILC2) or BM MDSC (BM, T cells + MDSC) 7 days after BMT.  Represents 2 combined experiment, (n=10 
or more per group).  Log-rank (Mantel-cox) test.  (E) Clinical scores of recipients from survival study in (g), ** 
p<0.01 by 2-way ANOVA, with Bonferroni correction for repeated measures of multiple comparisons.  (F) 
Expansion of human ILC2s (hILC2) from SR-1-stimulated CD34+ cord blood cells in the indicated cytokines.  
hILC2s were enumerated as CRTH2+/CD161-/Lin- cells (Supplemental Figure 6F) from days 3-21, n=3. 
 
